Visiongain Publishes Cardiology Information System Market Report 2020-2030

19 June 2020
Pharma

Visiongain has launched a new pharma report Cardiology Information System Market Report 2020-2030: Forecasts by System (Integrated Systems, Standalone Systems), Component (Software, Hardware, Services), End User (L3A Hospitals, L3B & L2 Hospitals, Level 1 Hospitals), and Geography (North America, Latin America, Europe, Asia Pacific, MEA).

The global Cardiology Information System Market is anticipated to grow at a lucrative CAGR of xyz% and anticipated to reach USD xyz million by 2020. Visiongain anticipates that the market is projected to witness a lucrative growth rate owing to the growing healthcare IT sector coupled with expansion in the global rise of cardiac disorders.

To access the data contained in this document please email contactus@visiongain.com

The cardiology information system is a digital collection of research software and clinical data and research material. CIS facilitates support for decisions, scientific advancement, exchange of information, and support for cardiovascular decision-making. CIS aims to support the advanced level of evidence-based professional standards in cardiac rehabilitation. Due to dynamic reporting, such as measurements, images, and information technology, the demand for cardiovascular systems has gained pace. Such information is structured according to a template, to ensure that patient reports are reliable and effective.

The presence of developed medical infrastructures and an increase in cardiovascular disease in North America currently has the largest share of the market. According to the Disease Control Center (CDC), in 2019 1 person died of cardiovascular disease every 37 seconds in the United States and approximately 647,000 people die each year. The increasing incidence of cardiovascular disorders, therefore, increases the need in this region to streamline the cardiac treatment system. Also, the market will continue to be driven by the existence of the target population and increased R&D investment by important business organizations.

Asia Pacific region is expected to experience the highest growth in terms of CAGR over the forecast period owing to the growing presence of a cardiac patient pool in markets such as India and China. Additionally, unmet needs of patients and untapped nations in this region have been attracting investments by global players and this is expected to boost the Cardiology Information System Market growth over the forecast period.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations, and launching new products to strengthen their position in the global cardiology information system market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the Cardiology Information System Market.

For instance, Royal Philips announced the launch of IntelliSpace Cardiovascular 4.1, its next-generation cardiovascular image, and the information management system. The latest version builds on the existing pediatric reporting capabilities, recognizing the important and unique nature of the pediatric environment. Clinicians can now complete their workflows more efficiently in a web browser, while integration with Philips Forcare enables the sharing of patient data between health systems and hospitals. New features also include enhanced security, enterprise protocols, and seamless access to Philips’ QLAB and TOMTEC software tools.

The comprehensive market report features companies such as Agfa Healthcare, Central Data Network, Cerner Corporation, Fujifilm Medical Systems, GE Healthcare, Merge Healthcare, Philips Healthcare, McKesson Corporation, Siemens Healthcare Private Limited, Infinitt Healthcare Co., Ltd. among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020-2030 for global markets such as North America, Latin America, Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Russia, India, Japan, China, Australia, ASEAN, GCC and South Africa.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

Read

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

Read

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

Read

Visiongain Publishes Artificial Intelligence (AI) in Drug Discovery Market Report 2021-2031

Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth.

01 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever